Well, my research on "Their" research says with stage 3 melanoma cancer there is a 37% recurrence rate the cancer will come back after getting the Neoadjuvant therapy, compared to 67% chance coming back if you just do the adjuvant. Furthermore, one study states 3 year survival rate for neoadjuvant to be 80% compared to just having adjuvant therapy at 60%. Another study states event free survival at 2 years with neo at 72% compared with just adjuvant at 49%. Thats a big difference. Therefore, it has been hypothesized that neoadjuvant therapy may be able to activate more antitumor T cells and improve clinical outcomes than administration of the same amount of drug delivered postoperatively. I'll have to ask about that signatera test. To answer your 3) question. I assume if the drug is indeed shrinking the tumor it would do the same to all the cancer cells in the body.